Cited 8 times in
Rate control and clinical outcomes in patients with atrial fibrillation and obstructive lung disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 양필성 | - |
dc.contributor.author | 유희태 | - |
dc.contributor.author | 정보영 | - |
dc.date.accessioned | 2019-12-18T00:18:44Z | - |
dc.date.available | 2019-12-18T00:18:44Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1547-5271 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/172972 | - |
dc.description.abstract | BACKGROUND: Rate-control medications are considered first-line treatment for patients with atrial fibrillation (AF). However, obstructive lung disease (OLD), a condition prevalent in those with AF, often makes it difficult to use those medications because of the lack of studies on new-onset AF in patients with OLD. OBJECTIVE: The purpose of this study was to investigate clinical outcomes after administration of each class of rate-control medication in patients with concomitant AF and OLD (AF-OLD). METHODS: This study used the entire database provided by the National Health Insurance Service from 2002 to 2015. Risk of all-cause mortality was compared between use of calcium channel blocker (CCB) and use of other drug classes in AF-OLD patients using Cox regression analyses after propensity score matching. RESULTS: Among the 13,111 patients, the number of AF-OLD patients treated with a CCB, cardioselective β-blocker (BB), nonselective BB, and digoxin was 2482, 2379, 2255, and 5995, respectively. The risk of mortality was lower with use of selective BB (hazard ratio [HR] 0.84; 95% confidence interval [CI] 0.75-0.94; P = .002) and nonselective BB (HR 0.85; 95% CI 0.77-0.95; P = .003) compared to use of CCBs. Digoxin use was related with worse survival, with marginal statistical significance (HR 1.09; 95% CI 1.00-1.18; P = .053). CONCLUSION: Among patients with AF-OLD, rate-control treatment using selective and nonselective BB was associated with a significant reduction in mortality compared with CCB use. Further prospective randomized trials are required to confirm these findings. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | HEART RHYTHM | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adrenergic beta-Antagonists/therapeutic use* | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anti-Arrhythmia Agents/therapeutic use | - |
dc.subject.MESH | Atrial Fibrillation/complications | - |
dc.subject.MESH | Atrial Fibrillation/drug therapy* | - |
dc.subject.MESH | Atrial Fibrillation/physiopathology | - |
dc.subject.MESH | Cause of Death/trends | - |
dc.subject.MESH | Digoxin/therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Heart Rate/drug effects | - |
dc.subject.MESH | Heart Rate/physiology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Diseases, Obstructive/complications* | - |
dc.subject.MESH | Lung Diseases, Obstructive/mortality | - |
dc.subject.MESH | Lung Diseases, Obstructive/physiopathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Propensity Score | - |
dc.subject.MESH | Republic of Korea/epidemiology | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Survival Rate/trends | - |
dc.title | Rate control and clinical outcomes in patients with atrial fibrillation and obstructive lung disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seng Chan You | - |
dc.contributor.googleauthor | Min Ho An | - |
dc.contributor.googleauthor | Dukyong Yoon | - |
dc.contributor.googleauthor | Ga-Young Ban | - |
dc.contributor.googleauthor | Pil-Sung Yang | - |
dc.contributor.googleauthor | Hee Tae Yu | - |
dc.contributor.googleauthor | Rae Woong Park | - |
dc.contributor.googleauthor | Boyoung Joung | - |
dc.identifier.doi | 10.1016/j.hrthm.2018.06.044 | - |
dc.contributor.localId | A02323 | - |
dc.contributor.localId | A02535 | - |
dc.contributor.localId | A03609 | - |
dc.relation.journalcode | J00980 | - |
dc.identifier.eissn | 1556-3871 | - |
dc.identifier.pmid | 30509364 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1547527118306702 | - |
dc.subject.keyword | Adrenergic beta-antagonist | - |
dc.subject.keyword | Atrial fibrillation | - |
dc.subject.keyword | Calcium channel blocker | - |
dc.subject.keyword | Digoxin | - |
dc.subject.keyword | Heart rate | - |
dc.subject.keyword | Obstructive lung disease | - |
dc.contributor.alternativeName | Yang, Pil Sung | - |
dc.contributor.affiliatedAuthor | 양필성 | - |
dc.contributor.affiliatedAuthor | 유희태 | - |
dc.contributor.affiliatedAuthor | 정보영 | - |
dc.citation.volume | 15 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1825 | - |
dc.citation.endPage | 1832 | - |
dc.identifier.bibliographicCitation | HEART RHYTHM, Vol.15(12) : 1825-1832, 2018 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.